Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: A sub-study of the DREAM trial

Diabetic Medicine

Volumn 31, Issue 9, 2014, Pages 1086-1092

  Punthakee, Z ^a   Almeras N ^b   Despres J P ^b,c   Dagenais, G R ^b,d   Anand, S S ^a   Hunt, D L ^a   Sharma, A M ^e   Jung, H ^a   Yusuf, S ^a   Gerstein, H C ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Department of Social and Preventive Medicine ^*  (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; FATTY ACID; GLUCOSE; INTERLEUKIN 6; PLACEBO; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE BLOOD LEVEL;

ABDOMINAL SUBCUTANEOUS FAT; ARTICLE; BLOOD SAMPLING; BODY COMPOSITION; BODY WEIGHT; COMPUTER ASSISTED TOMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DUAL ENERGY X RAY ABSORPTIOMETRY; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIP CIRCUMFERENCE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; ADULT; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; HUMAN; LIVER; MALE; METABOLISM; OBESITY; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADIPOKINES; ADULT; BLOOD GLUCOSE; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; FATTY ACIDS; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCOSE; HUMANS; INTRA-ABDOMINAL FAT; LIVER; MALE; OBESITY; THIAZOLIDINEDIONES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84906263508     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12512     Document Type: Article

References (30)

1. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790-797.
2. Hill MJ, Metcalfe D, McTernan PG. Obesity and diabetes: lipids, 'nowhere to run to'. Clin Sci (Lond) 2009; 116: 113-123.
3. Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res 2002; 10: 1008-1015.
4. Katoh S, Hata S, Matsushima M, Ikemoto S, Inoue Y, Yokoyama J et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy-a randomized controlled trial. Metabolism 2001; 50: 414-417.
5. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-293.
6. Smith SR, De JL, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism 2005; 54: 24-32.
7. Bertrand OF, Poirier P, Rodes-Cabau J, Rinfret S, Title LM, Dzavik V et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: a randomized placebo-controlled clinical trial. Atherosclerosis 2010; 211: 565-573.
8. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002; 51: 314-317.
9. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-2791.
10. Shadid S, Stehouwer CD, Jensen MD. Diet/exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers. J Clin Endocrinol Metab 2006; 91: 3418-3425.
11. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105.
12. Klain J, Fraser D, Goldstein J, Peiser J, Avinoah E, Ovnat A et al. Liver histology abnormalities in the morbidly obese. Hepatology 1989; 10: 873-876.
13. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia 2004; 47: 1519-1527.
14. Despres JP, Ross R, Boka G, Almeras N, Lemieux I. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009; 29: 416-423.
15. Sjostrom L, Kvist H, Cederblad A, Tylen U. Determination of total adipose tissue and body fat in women by computed tomography, 40K, and tritium. Am J Physiol 1986; 250: E736-E745.
16. von Eyben FE, Mouritsen E, Holm J, Montvilas P, Dimcevski G, Suciu G et al. Intra-abdominal obesity and metabolic risk factors: a study of young adults. Int J Obes Relat Metab Disord 2003; 27: 941-949.
17. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003; 285: E906-E916.
18. Davidson LE, Kuk JL, Church TS, Ross R. Protocol for measurement of liver fat by computed tomography. J Appl Physiol 2006; 100: 864-868.
19. Longo R, Ricci C, Masutti F, Vidimari R, Croce LS, Bercich L et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol 1993; 28: 297-302.
20. Ricci C, Longo R, Gioulis E, Bosco M, Pollesello P, Masutti F et al. Non-invasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997; 27: 108-113.
21. Shadid S, Stehouwer CD, Jensen MD. Diet/exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers. J Clin Endocrinol Metab 2006; 91: 3418-3425.
22. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-2791.
23. Anjana M, Sandeep S, Deepa R, Vimaleswaran KS, Farooq S, Mohan V. Visceral and central abdominal fat and anthropometry in relation to diabetes in Asian Indians. Diabetes Care 2004; 27: 2948-2953.
24. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 2000; 23: 465-471.
25. Kanaya AM, Harris T, Goodpaster BH, Tylavsky F, Cummings SR. Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. Diabetes Care 2004; 27: 1375-1380.
26. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003; 285: E906-E916.
27. Shah PK, Mudaliar S, Chang AR, Aroda V, Andre M, Burke P et al. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 505-510.
28. Yki-Jarvinen H. Thiazolidinediones and the liver in humans. Curr Opin Lipidol 2009; 20: 477-483.
29. Furnsinn C, Waldhausl W. Thiazolidinediones: metabolic actions in vitro. Diabetologia 2002; 45: 1211-1223.
30. Leal I, Romio SA, Schuemie M, Oteri A, Sturkenboom M, Trifiro G. Prescribing pattern of glucose-lowering drugs in the UK in the last decade: a focus on the effects of safety warnings about rosiglitazone. Br J Clin Pharmacol 2013; 75: 861-868.